Catherine A. Suever
Catherine A. Suever's purchase track record
Catherine A. Suever has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/3/2024 | HXL | $27K | -8.5% | -13.3% | +11.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Wells Fargo Lowers Hexcel Price Target to $105. Wells Fargo maintained its Overweight rating on Hexcel but reduced its price target to $105. The company also announced the schedule for its third-quarter 2026 earnings release. These updates provide new reference points for investors following Hexcel's recent performance.
Transaction History
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| HXL | ▲ Buy | Option Exercise | 2,697 | $0 | 5/8/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 290 | $40K | 6/30/2025 | View on chart |
| HXL | ▲ Buy | Option Exercise | 2,062 | $0 | 5/2/2025 | View on chart |
| INGR | ▲ Buy | Grant | 301 | $40K | 3/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 274 | $40K | 12/12/2024 | View on chart |
| HXL | ▲ Buy | Option Exercise | 326 | $0 | 10/6/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| HXL | ▲ Buy | Option Exercise | 288 | $0 | 7/14/2024 | View on chart |
| INGR | ▲ Buy | Grant | 346 | $40K | 6/28/2024 | View on chart |
| HXL | ▲ Buy | Option Exercise | 1,682 | $0 | 5/4/2024 | View on chart |
| HXL | ▲ Buy | Open Market | 400 | $27K | 5/3/2024 | View on chart |
| HXL | ▲ Buy | Option Exercise | 335 | $0 | 4/7/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| HXL | ▲ Buy | Option Exercise | 349 | $0 | 1/13/2024 | View on chart |
| INGR | ▲ Buy | Grant | 360 | $37K | 12/11/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 411 | $0 | 10/7/2023 | View on chart |
| INGR | ▲ Buy | Grant | 376 | $37K | 9/29/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 416 | $0 | 7/1/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 2,064 | $0 | 5/5/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 334 | $0 | 4/8/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 319 | $0 | 1/14/2023 | View on chart |
| HXL | ▲ Buy | Option Exercise | 294 | $0 | 10/9/2022 | View on chart |
| INGR | ▲ Buy | Grant | 450 | $37K | 10/3/2022 | View on chart |
| HXL | ▲ Buy | Option Exercise | 296 | $0 | 7/2/2022 | View on chart |
| INGR | ▲ Buy | Grant | 422 | $37K | 7/1/2022 | View on chart |
| HXL | ▲ Buy | Option Exercise | 2,230 | $0 | 5/10/2022 | View on chart |
| HXL | ▲ Buy | Option Exercise | 321 | $0 | 4/9/2022 | View on chart |
| INGR | ▲ Buy | Grant | 438 | $37K | 4/1/2022 | View on chart |
| HXL | ▲ Buy | Option Exercise | 378 | $0 | 1/15/2022 | View on chart |
| INGR | ▲ Buy | Grant | 391 | $38K | 1/3/2022 | View on chart |
| HXL | ▲ Buy | Option Exercise | 492 | $0 | 10/9/2021 | View on chart |
| INGR | ▲ Buy | Grant | 359 | $32K | 10/1/2021 | View on chart |
| INGR | ▲ Buy | Grant | 181 | $16K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target
Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.